The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of depth of target lesion response to brigatinib with outcomes in patients with ALK inhibitor-naive ALK+ NSCLC in ALTA-1L.
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; bio-thera; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Hengrui Pharmaceutical; Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; Puma Biotechnology; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Hye Ryun Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
 
Myung-Ju Ahn
Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN
Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN
Research Funding - YUHAN
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst); Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Ji-Youn Han
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Takeda
Research Funding - Ono Pharmaceutical; Pfizer; Roche; Takeda
 
Maximilian Hochmair
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; Merck Sharp & Dohme; Novartis; Roche; Takeda
 
Ki Hyeong Lee
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Pfizer
 
Angelo Delmonte
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
 
Rosario Garcia Campelo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda
Travel, Accommodations, Expenses - MSD Oncology; Pfizer; Roche/Genentech
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo
 
Frank Griesinger
Consulting or Advisory Role - Amgen; ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Siemens; Takeda
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Janssen; Lilly; Merck Serono; MSD Oncology; Novartis; Peptomyc; Pfizer; Roche; Sanofi; Takeda
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; CME outfitters; Lilly; Medscape; Merck Sharp & Dohme; PeerVoice; Pfizer; Roche; Takeda
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRÍFOLS
 
Raffaele Califano
Stock and Other Ownership Interests - The Christie Private Care
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Lilly; MSD; Roche; Takeda
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Michael Thomas
Honoraria - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Scott N. Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck (Inst); NextCure (Inst)
 
Marcello Tiseo
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi; Takeda
Research Funding - AstraZeneca; Boehringer Ingelheim
 
Yuyin Liu
Employment - Takeda
 
Pingkuan Zhang
Employment - Takeda
 
Sanjay Popat
Honoraria - Amgen; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche; Seagen; Takeda; Turning Point Therapeutics; Xcovery
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Guardant Health; Incyte; Janssen; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Pfizer; Roche; Seagen; Takeda; Turning Point Therapeutics; Xcovery
Research Funding - ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics; MSD (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trizell; Turning Point Therapeutics (Inst)
Expert Testimony - Merck KGaA; Roche